The purpose of this study is to assess the long-term efficacy and safety of latanoprost monotherapy in patients with normal tension glaucoma (NTG) using a prospective, observational design. Visits were scheduled at 6-month intervals for 24 months. Intraocular pressure (IOP), optic nerve head findings, visual field status, and adverse events were recorded.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change From Baseline in Raw Intraocular Pressure (IOP) by Visit
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24, Last Visit
Number of Participants With a 24-Hour Intraocular Pressure (IOP) Profile: Month 12
Timeframe: Month 12
Number of Participants With a 24-Hour Intraocular Pressure (IOP) Profile: Month 24
Timeframe: Month 24
Number of Participants Per Visit With Intraocular Pressure (IOP) 24-Hour Pressure Peaks: Month 12
Timeframe: Month 12
Number of Participants Per Visit With Intraocular Pressure (IOP) 24-Hour Pressure Peaks: Month 24
Timeframe: Month 24
Percentage of Participants Who Achieved Intraocular Pressure (IOP) Target at Last Visit
Timeframe: Month 24, (or last visit)
Change From Baseline by Visit in Optic Disc Excavation: Horizontal Cup to Disc Ratio
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24, Last Visit
Change From Baseline by Visit in Optic Disc Excavation: Vertical Cup to Disc Ratio
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24, Last Visit
Number of Participants With Optic Disc Hemorrhage by Visit: Month 6
Timeframe: Month 6
Number of Participants With Optic Disc Hemorrhage by Visit: Month 12
Timeframe: Month 12
Number of Participants With Optic Disc Hemorrhage by Visit: Month 18
Timeframe: Month 18
Number of Participants With Optic Disc Hemorrhage by Visit: Month 24
Timeframe: Month 24
Change From Baseline in Heidelberg Retina Tomograph (HRT) Parameters: Rim Area
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24, Last Visit
Change From Baseline in Heidelberg Retina Tomograph (HRT) Parameters: Rim Volume
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24, Last Visit
Change From Baseline in Heidelberg Retina Tomograph Parameters: Cup Shape Measure
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24, Last Visit
Change From Baseline in Heidelberg Retina Tomograph (HRT) Parameters: Mean RNFL Thickness
Timeframe: Baseline, Month 6, Month 12, Month 18, Month 24, Last Visit
Number of Participants With Change From Baseline to Month 24 in Aulhorn Stages
Timeframe: Baseline, Month 24
Number of Participants With Change From Baseline to Month 24 in Visual Field Defect
Timeframe: Baseline, Month 24
Number of Participants With Investigator Assessments of Efficacy at Month 24
Timeframe: Month 24
Number of Participants With Individual Progression of Glaucoma Damage: Horizontal Cup to Disc Ratio and/or Vertical Cup to Disc Ratio
Timeframe: Month 24 (or last visit)
Number of Participants With Individual Progression of Glaucoma Damage: Optic Disc Hemorrhage
Timeframe: Month 24 (or last visit)
Number of Participants With Individual Progression of Glaucoma Damage: Rim Area, Rim Volume, or Mean Retinal Nerve Fiber Layer (RNFL) Thickness
Timeframe: Month 24 (or last visit)
Number of Participants With Individual Progression of Glaucoma Damage: Visual Field Defect-Deterioration
Timeframe: Month 24 (or last visit)
Number of Participants With Individual Progression of Glaucoma Damage: Aulhorn Stage
Timeframe: Month 24 (or last visit)
Number of Participants With Individual Progression of Glaucoma Damage: Mean Defect
Timeframe: Month 24 (or last visit)
Percentage of Participants With Overall Progression of Glaucoma Damage
Timeframe: Month 24 (or last visit)
Percentage of Participants With Progression of Optic Disc Excavation
Timeframe: Month 24 (or last visit)
Percentage of Participants With Progression of Visual Field
Timeframe: Month 24 (or last visit)